Universal Vision Biotechnology Co., Ltd.

TPEX:3218 Stock Report

Market Cap: NT$17.2b

Universal Vision Biotechnology Future Growth

Future criteria checks 2/6

Universal Vision Biotechnology is forecast to grow earnings and revenue by 10% and 6.9% per annum respectively. EPS is expected to grow by 10% per annum. Return on equity is forecast to be 27.4% in 3 years.

Key information

10.0%

Earnings growth rate

10.0%

EPS growth rate

Healthcare earnings growth19.0%
Revenue growth rate6.9%
Future return on equity27.4%
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Universal Vision Biotechnology (GTSM:3218) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 03
Universal Vision Biotechnology (GTSM:3218) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

The Case For Universal Vision Biotechnology Co., Ltd. (GTSM:3218): Could It Be A Nice Addition To Your Dividend Portfolio?

Mar 26
The Case For Universal Vision Biotechnology Co., Ltd. (GTSM:3218): Could It Be A Nice Addition To Your Dividend Portfolio?

Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Shares Could Be 39% Below Their Intrinsic Value Estimate

Mar 08
Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Shares Could Be 39% Below Their Intrinsic Value Estimate

The 22% Return On Capital At Universal Vision Biotechnology (GTSM:3218) Got Our Attention

Feb 07
The 22% Return On Capital At Universal Vision Biotechnology (GTSM:3218) Got Our Attention

Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Jan 17
Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Universal Vision Biotechnology (GTSM:3218) Seems To Use Debt Rather Sparingly

Dec 27
Universal Vision Biotechnology (GTSM:3218) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Universal Vision Biotechnology Co., Ltd. (GTSM:3218)

Dec 06
Estimating The Fair Value Of Universal Vision Biotechnology Co., Ltd. (GTSM:3218)

Earnings and Revenue Growth Forecasts

TPEX:3218 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,865N/AN/AN/A2
12/31/20254,5681,210N/AN/A3
12/31/20244,2471,078N/AN/A3
9/30/20244,1831,0791,2211,634N/A
6/30/20244,1651,1011,1211,543N/A
3/31/20244,1251,0831,1141,569N/A
12/31/20234,0821,0451,0791,554N/A
9/30/20234,0471,0369691,480N/A
6/30/20233,8979769691,416N/A
3/31/20233,6879038861,348N/A
12/31/20223,4948517751,268N/A
9/30/20223,2737918011,250N/A
6/30/20223,0327198241,300N/A
3/31/20222,8576597781,141N/A
12/31/20212,632595583912N/A
9/30/20212,469538484822N/A
6/30/20212,399556392722N/A
3/31/20212,269543461805N/A
12/31/20202,053483529827N/A
9/30/20201,865422398669N/A
6/30/20201,628322365607N/A
3/31/20201,503281257500N/A
12/31/20191,419238180419N/A
9/30/20191,340226204409N/A
6/30/20191,285214110306N/A
3/31/20191,233188154326N/A
12/31/20181,19516167273N/A
9/30/20181,16514424226N/A
6/30/20181,144146N/A244N/A
3/31/20181,107130N/A229N/A
12/31/20171,082120N/A236N/A
9/30/20171,085131N/A269N/A
6/30/20171,068102N/A239N/A
3/31/20171,07296N/A223N/A
12/31/20161,07392N/A255N/A
9/30/20161,03862N/A210N/A
6/30/20161,03175N/A240N/A
3/31/20161,01469N/A221N/A
12/31/20151,01481N/A184N/A
9/30/20151,01689N/A222N/A
6/30/20151,01392N/A253N/A
3/31/20151,00093N/A226N/A
12/31/2014988102N/A222N/A
9/30/2014992119N/A189N/A
6/30/2014972118N/A173N/A
3/31/2014945107N/A229N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3218's forecast earnings growth (10% per year) is above the savings rate (1.1%).

Earnings vs Market: 3218's earnings (10% per year) are forecast to grow slower than the TW market (19.2% per year).

High Growth Earnings: 3218's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3218's revenue (6.9% per year) is forecast to grow slower than the TW market (12.4% per year).

High Growth Revenue: 3218's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3218's Return on Equity is forecast to be high in 3 years time (27.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 12:31
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Universal Vision Biotechnology Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeCapital Securities Corporation
Hui-Chao HsuCitigroup Inc
Corinne JianMacquarie Research